Throughout January, we observe Cervical Cancer Awareness Month (CCAM) as a time to raise awareness of the problem and magnify our support of the World Health Organization (WHO) global strategy to eliminate cervical cancer as a public health problem.
The International Journal of Gynecological Cancer (IJGC) is also joining the movement by offering free access to a selection of research articles and reviews from the past year.
Cervical Cancer Awareness Month seeks to promote routine screenings and early detection through Pap smears and HPV testing; to encourage individuals, particularly adolescents, to get vaccinated against HVP to reduce the risk of developing cervical cancer; to educate individuals about the risk factors for and early symptoms of the disease; to reduce the stigma and fear associated with cervical cancer; to advocate for access to healthcare services, particularly in underserved communities; and to provide support, resources, and a sense of community for those affected, including patients, families, and caregivers.
Additional information may be found at
https://igcs.org/cervical-cancer-awareness/
Cibula D, Raspollini MR, Planchamp F, et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*. International Journal of Gynecological Cancer 2023;33:649-666
Parpinel G, Laas-Faron E, Balaya V, et al. Survival after sentinel lymph node biopsy for early cervical cancers: a systematic review and meta-analysis. International Journal of Gynecological Cancer 2023;33:1853-1860
Xia L, Wang J, Wang C, et al. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. International Journal of Gynecological Cancer 2023;33:1861-1868
Salcedo MP, Lathrop E, Osman N, et al. The Mulher Study: cervical cancer screening with primary HPV testing in Mozambique. International Journal of Gynecological Cancer 2023;33:1869-1874
Nitecki R, Ramirez PT, Dundr P, et al. MILACC study: could undetected lymph node micrometastases have impacted recurrence rate in the LACC trial? International Journal of Gynecological Cancer 2023;33:1684-1689
Frumovitz M, Morani AC, Aziz A, et al. PET/CT scan improves detection of metastatic disease compared with CT scan alone in women with high-grade neuroendocrine cervical cancer: a NeCTuR study. International Journal of Gynecological Cancer 2023;33:1690-1694
Michaan N, Wenkert A, Even-Sapir E, et al. Prognostic significance of delayed complete metabolic response on PET/CT after primary chemoradiation treatment of cervical cancer. International Journal of Gynecological Cancer 2023;33:1695-1701
Nakisige C, de Fouw M, Kabukye J, et al. Artificial intelligence and visual inspection in cervical cancer screening. International Journal of Gynecological Cancer 2023;33:1515-1521
Bizzarri N, Russo L, Dolciami M, et al. Radiomics systematic review in cervical cancer: gynecological oncologists’ perspective. International Journal of Gynecological Cancer 2023;33:1522-1541
Phoolcharoen N, Areeruk W, Kantathavorn N, et al. Self- and physician-collected high-risk human papillomavirus (HPV) testing to detect high-grade cervical lesions among Thai women. International Journal of Gynecological Cancer 2023;33:1354-1358
Salvo G, Flores Legarreta A, Ramalingam P, et al. Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study. International Journal of Gynecological Cancer 2023;33:1359-1369
Mauro J, Viveros-Carreño D, Vizzielli G, et al. Survival after sentinel node biopsy alone in early-stage cervical cancer: a systematic review. International Journal of Gynecological Cancer 2023;33:1370-1375
Viveros-Carreño D, Vieira-Serna S, Grillo-Ardila CF, et al. Definitive pelvic radiotherapy for patients with newly diagnosed stage IVB cervical cancer: a systematic review. International Journal of Gynecological Cancer 2023;33:1057-1062
Chargari C, Tanderup K, Planchamp F, et al. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer. International Journal of Gynecological Cancer 2023;33:862-875
Snyman LC, Richter KL, Lukhwareni A, et al. Cytology compared with Hybrid Capture 2 human papilloma virus cervical cancer screening in HIV positive and HIV negative South African women. International Journal of Gynecological Cancer 2023;33:669-675
Ishikawa M, Shibata T, Kataoka T on behalf of the Gynecologic Cancer Study Group in Japan Clinical Oncology Group, et al. Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311). International Journal of Gynecological Cancer 2023;33:692-700
Carneiro VCG, Batista TP, Andrade MR, et al. Proof-of-concept randomized phase II non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer ≤2 cm (LESSER). International Journal of Gynecological Cancer 2023;33:498-503
Gomez Cherey JF, Payalef SN, Fleider L, et al. Microbiota unbalance in relation to high-risk human papillomavirus cervical infection. International Journal of Gynecological Cancer 2023;33:482-488
Bizzarri N, Chiantera V, Loverro M, et al. Minimally invasive versus open pelvic exenteration in gynecological malignancies: a propensity-matched survival analysis. International Journal of Gynecological Cancer 2023;33:190-197
Suzuki Y, Huang Y, Ferris J, et al. Prescription of hormone replacement therapy among cervical cancer patients with treatment-induced premature menopause. International Journal of Gynecological Cancer 2023;33:26-34